Currency In USD
| Previous Close | 6.8 |
| Open | 6.92 |
| Day High | 6.92 |
| Day Low | 6.7 |
| 52-Week High | 34.25 |
| 52-Week Low | 4.91 |
| Volume | 17,423.25 |
| Average Volume | 56,806 |
| Market Cap | 8.6M |
| PE | -1.84 |
| EPS | -3.71 |
| Moving Average 50 Days | 7.54 |
| Moving Average 200 Days | 11.24 |
| Change | 0.02 |
GT Biopharma to Participate in the 38th Annual Roth Conference
GlobeNewswire Inc.
Mar 11, 2026 11:00 AM GMT
SAN FRANCISCO, CALIFORNIA, March 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural
GT Biopharma Reports Full Year 2025 Financial Results
GlobeNewswire Inc.
Mar 02, 2026 12:00 PM GMT
Phase 1 trial evaluating GTB-3650 TriKE® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
GlobeNewswire Inc.
Feb 17, 2026 12:30 PM GMT
SAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural